Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Ferring signs telemedicine collaboration with Danish hospital

Will work with North Zealand University Hospital on IBD patient care

Ferring Pharmaceuticals headquarters 

Ferring Pharmaceuticals has signed a telemedicine deal with a Copenhagen hospital that it hopes will transform patient care in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

The Swiss firm will collaborate with North Zealand University Hospital in a multi-year partnership that will be fully funded by Ferring but governed by the hospital.

Ferring's executive VP and chief scientific officer Per Falk said: “Ferring and North Zealand University Hospital both fully embrace the concept of eHealth and its positive effects in relation to patient empowerment.

“This partnership will assure continued focus on eHealth and generate personalised treatment for IBD patients.”

Details of the work are fairly sparse at this stage, with Ferring saying only that it will be using “an innovative eHealth platform” that allows patients to self-monitor and self-treat.

And a company spokesperson told PMLiVE:"This platform and the way it will be used are still under work and that the next step in the roll-out of this initiative will be on August 30 - when a symposium will be held in Copenhagen focusing on the microbiome and eHealth."

It will do this by enabling them to “screen for disease activity, act proactively on their symptoms and increase adherence to therapy”, the pharma firm said in a statement.

North Zealand University Hospital's Professor Pia Munkholm said: “In my clinical practice, IBD patients who are monitored by an e-health programme have a reduced time-to-remission. 

“This effect is linked to the patient's ability to more tightly monitor their condition on the web than in a standard care setting, giving users of the eHealth programme the opportunity to detect a relapse sooner.”

The partners' eHealth work will also focus on evaluating the role of the microbiome - the genes within a person's microbes - in the way patients respond to different treatments.

24th May 2016

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics